Interpace Diagnostics Group, Inc. develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules. The company's customers consist primarily of physicians, hospitals, and clinics. The company was formerly known as PDI, Inc. and changed its name to Interpace Diagnostics Group, Inc. in December 2015. Interpace Diagnostics Group, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Services
SectorMedical
Current SymbolNASDAQ:IDXG
Previous Symbol
CUSIP69329V10
Phone855-776-6419
Debt
Debt-to-Equity RatioN/A
Current Ratio2.61
Quick Ratio2.61
Price-To-Earnings
Trailing P/E Ratio-1.46
Forward P/E Ratio-3.37
P/E GrowthN/A
Sales & Book Value
Annual Sales$15.90 million
Price / Sales2.12
Cash FlowN/A
Price / CashN/A
Book Value$1.48 per share
Price / Book0.80
Profitability
EPS (Most Recent Fiscal Year)($0.81)
Net Income$-12,210,000.00
Net Margins-64.40%
Return on Equity-32.95%
Return on Assets-24.64%
Miscellaneous
Employees75
Outstanding Shares28,590,000
Market Cap$33.46 million
OptionableNot Optionable
Interpace Diagnostics Group (NASDAQ:IDXG) Frequently Asked Questions
What is Interpace Diagnostics Group's stock symbol?
Interpace Diagnostics Group trades on the NASDAQ under the ticker symbol "IDXG."
How were Interpace Diagnostics Group's earnings last quarter?
Interpace Diagnostics Group Inc (NASDAQ:IDXG) posted its quarterly earnings data on Tuesday, November, 13th. The business services provider reported ($0.11) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.07) by $0.04. The business services provider had revenue of $5.75 million for the quarter, compared to analysts' expectations of $5.50 million. Interpace Diagnostics Group had a negative net margin of 64.40% and a negative return on equity of 32.95%. View Interpace Diagnostics Group's Earnings History.
When is Interpace Diagnostics Group's next earnings date?
What guidance has Interpace Diagnostics Group issued on next quarter's earnings?
Interpace Diagnostics Group issued an update on its FY 2018 earnings guidance on Wednesday, October, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $20 million, compared to the consensus revenue estimate of $21.5 million.
What price target have analysts set for IDXG?
5 analysts have issued twelve-month target prices for Interpace Diagnostics Group's stock. Their forecasts range from $2.25 to $4.50. On average, they anticipate Interpace Diagnostics Group's stock price to reach $3.55 in the next twelve months. This suggests a possible upside of 200.8% from the stock's current price. View Analyst Price Targets for Interpace Diagnostics Group.
What is the consensus analysts' recommendation for Interpace Diagnostics Group?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Interpace Diagnostics Group in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Interpace Diagnostics Group.
What are Wall Street analysts saying about Interpace Diagnostics Group stock?
Here are some recent quotes from research analysts about Interpace Diagnostics Group stock:
- 1. According to Zacks Investment Research, "Interpace Diagnostics Group, Inc. provides molecular diagnostic tests. The company's test consists of ThyGenX Thyroid Oncogene Panel (R), Thyroid miRNA(TM) and PancraGen(TM). Interpace Diagnostics Group Inc, formerly known as PDI Inc., is headquartered in Parsippany, New Jersey. " (11/17/2018)
- 2. HC Wainwright analysts commented, "Our price target is derived from a market value of the firm at $115M, which includes a discounted cash flow analysis based asset value for the company’s three commercialized laboratory- developed tests (LDTs), with a 15% discount rate and a 2% terminal growth rate." (11/8/2018)
- 3. Maxim Group analysts commented, "Interpace presented new interim data at the Annual Meeting of the American Thyroid Association (ATA) on the combined use of its molecular tests for thyroid cancer; ThyGenX and ThyraMIR." (10/15/2018)
Has Interpace Diagnostics Group been receiving favorable news coverage?
News coverage about IDXG stock has been trending somewhat positive recently, InfoTrie reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Interpace Diagnostics Group earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned news coverage about the business services provider a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days.
Who are some of Interpace Diagnostics Group's key competitors?
Some companies that are related to Interpace Diagnostics Group include Alphatec (ATEC), RenovaCare (RCAR), RA Medical Systems (RMED), Endologix (ELGX), Sensus Healthcare (SRTS), Restoration Robotics (HAIR), Invo Bioscience (IVOB), STRATA Skin Sciences (SSKN), Apollo Endosurgery (APEN), Repro-Med Systems (REPR), Pro-Dex (PDEX), Arch Therapeutics (ARTH), CAS Medical Systems (CASM), Motus GI (MOTS) and iCAD (ICAD).
Who are Interpace Diagnostics Group's key executives?
Interpace Diagnostics Group's management team includes the folowing people:
- Mr. Jack E. Stover, CEO, Pres and Director (Age 65)
- Mr. James E. Early, CFO, Sec. & Treasurer (Age 64)
- Mr. Gregory Richard, Sr. VP & Chief Commercial Officer (Age 51)
- Mr. Thomas John Freeburg, Chief Accounting Officer (Age 50)
- Mr. Patrick Kane, VP & Corp. Controller
Who are Interpace Diagnostics Group's major shareholders?
Interpace Diagnostics Group's stock is owned by a number of of institutional and retail investors. Top institutional investors include Perkins Capital Management Inc. (2.23%), Essex Investment Management Co. LLC (1.06%), Virtu Financial LLC (0.53%), JPMorgan Chase & Co. (0.44%) and JPMorgan Chase & Co. (0.44%). View Institutional Ownership Trends for Interpace Diagnostics Group.
Which institutional investors are buying Interpace Diagnostics Group stock?
How do I buy shares of Interpace Diagnostics Group?
Shares of IDXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Interpace Diagnostics Group's stock price today?
One share of IDXG stock can currently be purchased for approximately $1.18.
How big of a company is Interpace Diagnostics Group?
Interpace Diagnostics Group has a market capitalization of $33.46 million and generates $15.90 million in revenue each year. The business services provider earns $-12,210,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Interpace Diagnostics Group employs 75 workers across the globe.
What is Interpace Diagnostics Group's official website?
How can I contact Interpace Diagnostics Group?
Interpace Diagnostics Group's mailing address is MORRIS CORPORATE CENTER 1 BUILDING C 300 INTERPACE PARKWAY, PARSIPPANY NJ, 07054. The business services provider can be reached via phone at 855-776-6419 or via email at [email protected]
MarketBeat Community Rating for Interpace Diagnostics Group (NASDAQ IDXG)
MarketBeat's community ratings are surveys of what our community members think about Interpace Diagnostics Group and other stocks. Vote "Outperform" if you believe IDXG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IDXG will underperform the S&P 500 over the long term. You may vote once every thirty days.
